IEQ Capital
GLUE icon

IEQ Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

IEQ Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-18,959
Closed -$459K – 2066
2026
Q2 		$459K Sell
18,959
-43,744
-70% -$827K ﹤0.01% 1434
2026
Q1 		$1.03M Sell
62,703
-26,565
-30% -$508K ﹤0.01% 1037
2025
Q4 		$1.4M Buy
89,268
+30,202
+51% +$407K ﹤0.01% 907
2025
Q3 		$438K Sell
59,066
-14,909
-20% -$79K ﹤0.01% 1364
2025
Q2 		$334K Buy
+73,975
New +$330K ﹤0.01% 1339

Other funds holding GLUE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Versant Venture Management
Versant Venture Management San Francisco, California $109M AUM 43.78% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

IEQ Capital's GLUE Position: Q3 2026 in Review

IEQ Capital sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 18,959 shares — an estimated $459K sold.

IEQ Capital first reported a position in GLUE in Q2 2025 and held it in 5 quarters. The position peaked at $1.4M in Q4 2025. 124 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • IEQ Capital reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
  • IEQ Capital sold 18,959 Monte Rosa Therapeutics shares in Q3 2026, an estimated $459K.
  • IEQ Capital first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 5 quarters.
  • IEQ Capital's Monte Rosa Therapeutics position peaked at $1.4M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on IEQ Capital's 13F filing for Q3 2026, filed 10 Nov 2026.